Physician profile
Todd Price
NPI 1699784819
$4,580.56
in general payments reported to CMS, 2019-2025
16 companies · $763 in 2025
The $763 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $366 · 2021: $303 · 2022: $817 · 2023: $937 · 2024: $630 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,101.52 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $765.26 | 2022-2025 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $491.46 | 2021-2025 | Vibativ |
| Shionogi INC | $472.34 | 2022-2025 | Fetroja |
| E.R. Squibb & Sons, L.L.C. | $433.77 | 2019-2022 | |
| Insmed, INC. | $283.57 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $271.68 | 2019-2020 | |
| Allergan, INC. | $218.87 | 2019-2020 | |
| Abbott Laboratories | $126.72 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $121.84 | 2022 | |
| Merck Sharp & Dohme LLC | $98.65 | 2019-2022 | |
| Gilead Sciences, INC. | $57.22 | 2025 | |
| La Jolla Pharmaceutical Company | $55.51 | 2023-2025 | Xerava, Zevtera |
| Mayne Pharma Commercial LLC | $33.19 | 2020 | |
| Janssen Biotech, INC. | $24.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $24.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.